波士顿科学(BSX)最主要的收入来源是什么？

通过最新财报数据拆解，该公司的收入主要由其核心业务板块与相关服务支持构成。您可以通过页面上的交互式图表直观查看各业务线对总营收的具体贡献比例。

如何直观分析 BSX 的财务状况与盈利模式？

瓜壳日历通过交互式桑基图(Sankey Diagram)和瀑布图(Waterfall Chart)，将该公司的总营收、销售成本、运营费用以及最终的净利润流程进行了全景可视化，方便投资者一分钟看懂其经营效率与现金流走向。

Income Statement Q1 2026
Item	Category	Value	YoY
Net sales	revenue	5.20B	11.58%
Gross profit	profit	3.61B	12.59%
Cost of products sold (excluding amortization expense)	cost	1.59B	9.43%
Other, net	revenue	151.00M	344.12%
Operating income (loss)	profit	1.10B	19.54%
Contingent consideration net expense (benefit)	cost	30.00M	500.00%
Operating expenses	cost	2.51B	9.83%
Aggregate	revenue	1.25B
Aggregate	cost	2.54B
Income tax expense (benefit)	cost	176.00M	32.33%
Income (loss) before income taxes	profit	1.16B	44.35%
Interest expense, operating and nonoperating	cost	90.00M	9.76%
Selling, general and administrative expenses	cost	1.78B	11.52%
Research and development expenses	cost	516.00M	16.48%
Amortization expense	cost	232.00M	5.94%
Royalty expense	cost	12.00M	-14.29%
Restructuring charges	cost	3.00M	-70.00%
Net income (loss) attributable to noncontrolling interests	cost	2.00M	0.00%
Net income (loss)	profit	1.34B	99.26%
Net income (loss) attributable to boston scientific common stockholders	profit	1.34B	98.96%

Business Breakdown
Segment	Value	YoY
Cardiovascular	3.50B	13.55%
MedSurg	1.70B	7.86%

Products Breakdown
Segment	Value	YoY
Interventional Cardiology Therapies	1.24B	10.68%
Electrophysiology (EP)	905.00M	23.97%
Global Endoscopy (Endo) Reporting Unit	736.00M	9.36%
Global Urology and Pelvic Health Reporting Unit	646.00M	2.05%
Cardiac Rhythm Management	578.00M	0.00%
Watchman	506.00M	19.06%
Global Neuromodulation (NM) Reporting Unit	318.00M	17.34%
Interventional Oncology And Embolization	268.00M	17.54%
Others	2.00M	100.00%

Balance Sheet Q1 2026
Item	Category	Value
Inventories	assets	3.12B
Trade accounts receivable, net	assets	3.03B
Cash and cash equivalents	assets	1.45B
Other current assets	assets	729.00M
Prepaid income taxes	assets	358.00M
Total current assets	assets	8.68B
Goodwill	assets	18.54B
Other intangible assets, net	assets	7.06B
Property, plant, and equipment and finance lease right-of-use asset, after accumulated depreciation and amortization	assets	4.06B
Deferred tax assets	assets	3.95B
Other assets, noncurrent	assets	2.05B
Total assets	assets	44.35B
Total equity	liabilities	26.10B
Long-term debt	liabilities	10.99B
Total current liabilities	liabilities	4.57B
Other liabilities, noncurrent	liabilities	2.47B
Deferred tax liabilities	liabilities	219.00M
Noncontrolling interests	liabilities	240.00M
Treasury stock, value	equity	2.25B
Accumulated other comprehensive income (loss), net of tax	equity	398.00M
Total stockholders’ equity	equity	25.86B
Accrued liabilities, current	liabilities	2.51B
Accounts payable, current	liabilities	1.14B
Other liabilities, current	liabilities	875.00M
Debt, current	liabilities	41.00M
Aggregate	equity	28.51B
Additional paid-in capital	equity	21.58B
Retained earnings	equity	6.91B
Common stock, $0.01 par value - authorized 2,000,000,000 shares - 1,749,584,151 shares issued as of march 31, 2026 and 1,746,290,165 shares issued as of december 31, 2025	equity	17.00M

Operating Activities – 3M 2026
Item	Value
Net income (loss)	1.34B
Depreciation and amortization	351.00M
Stock-based compensation expense	83.00M
Other, net	27.00M
Inventory step-up amortization	2.00M
Contingent consideration net expense (benefit)	-30.00M
Increase (decrease) in other operating assets	-109.00M
Increase (decrease) in accounts receivable	-117.00M
Gain (loss) on investments	-158.00M
Increase (decrease) in inventories	-177.00M
Deferred and prepaid income taxes	-351.00M
Accounts payable, accrued expenses and other liabilities	-512.00M

Investing Activities – 3M 2026
Item	Value
Proceeds from (payments for) investments and acquisitions of certain technologies	61.00M
Payment for (proceeds from) other investing activity	48.00M
Payments to acquire property, plant, and equipment	-177.00M
Payment for acquisition	-523.00M

Financing Activities – 3M 2026
Item	Value
Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans	81.00M
Other, net	3.00M
Payment to net share settle employee equity awards	-85.00M
Repayments of short-term debt	-259.00M

Cash Balance – 3M 2026
Item	Value
Cash and cash equivalents, beginning of period	2.15B
Cash and cash equivalents, end of period	1.64B